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FIRST. TRANSFORMATIVE. PROVEN. 
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This presentation may contain statements of a forward-looking nature relating to 
future events. Statements contained in this presentation that are forward-
looking statements are intended to be made pursuant to the Safe Harbor 
Provisions of the Private Securities Litigation Reform Act of 1995.  These 
forward-looking statements are subject to the inherent uncertainties in 
predicting future results and conditions.  These statements reflect the 
Company’s current beliefs, and a number of important factors could cause actual 
results to differ materially from those expressed herein.  

Please see the Company’s Annual Report on Form 10-K, as well as subsequent 
filings, filed with the Securities and Exchange Commission for a more detailed 
discussion of the risks and uncertainties associated with the Company’s business, 
including but not limited to the risks and uncertainties associated with venture 
capital investing and other significant factors that could affect the Company’s 
actual results.  Except as otherwise required by Federal securities laws, Harris & 
Harris Group, Inc. undertakes no obligation to update or revise these forward-
looking statements to reflect new events or uncertainties.
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SAFE HARBOR STATEMENT
HARRIS & HARRIS GROUP
Harris & Harris Group 
is an Early-Stage, 
Active Investor 
in Transformative 
Nanotechnology Companies.
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NANOTECHNOLOGY ADDRESSES MEGATRENDS 
•  Governments,	  
corpora/ons,	  and	  
investors	  increasingly	  
organize	  their	  R&D,	  new	  
business,	  and	  funding	  
eﬀorts	  around	  addressing	  
megatrends.	  	  
•  Nanotechnology	  is	  
fundamentally	  	  
posi/oned	  to	  address	  	  	  
the	  needs	  created	  by	  	  
the	  most	  important	  
megatrends.	  	  
Global	  health	  and	  
ageing	  population	  
Ubiquitous	  	  
data	  and	  	  
connectivity	  
Nanotechnology	  
Impact	  	  
Global	  
energy	  	  
needs	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•  Compound	  Annual	  Growth	  Rate	  of:	  
•  21.5%	  for	  total	  funding	  from	  2000	  to	  2010	  
•  35.0%	  for	  corporate	  R&D	  funding	  from	  2000	  to	  $9	  Billion	  in	  2010	  
•  19.5%	  for	  global	  publica/ons	  from	  2000	  to	  2010	  
TOTAL	  GLOBAL	  
REVENUE	  
2004	   2009	   2015	  
Nanomaterials	   $0.29	  B	   $1	  B	   $2.9	  B	  
Nanointermediates	   $2.5	  B	   $27	  B	   $474	  B	  
Nano-­‐enabled	  products	   $16	  B	   $223	  B	   $1960	  B	  
2015	  numbers	  are	  projected	  
Source:	  Lux	  Research	  Inc.	  
By	  2015,	  $2	  trillion	  in	  products	  projected	  to	  incorporate	  nanotechnology.	  
NANOTECHNOLOGY COMMERCIALIZATION IS NOW 

Note:	  There	  is	  no	  guarantee	  that	  2015	  projec/ons	  will	  be	  achieved.	  	  Do	  not	  place	  undue	  reliance	  on	  such	  projec/ons.	  	  	  
Harris	  &	  Harris	  Group	  does	  not	  warrant	  the	  accuracy,	  completeness	  or	  /meliness	  of	  informa/on	  cited	  from	  third-­‐party	  sources.	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NANOTECHNOLOGY IS POSITIONED 
FOR RAPID ADVANCEMENT
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•  Carbon	  Nanotubes	  	  
	  Discovered	  
•  First	  liquidity	  events	  
•  PorLolio	  Company	  	  
	  Revenue	  Growth	  of	  42%	  
•  Assembled	  Team	  
•  First	  Investments	  •  Term	  “Nanotechnology”	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We	  believe	  we	  are	  the	  leaders	  invesCng	  in	  nanotechnology,	  	  
and	  its	  growth	  is	  allowing	  us	  potenCally	  to	  deploy	  more	  funds	  proﬁtably.	  
Note:	  There	  is	  no	  guarantee	  that	  the	  projec/ons	  on	  this	  slide	  will	  be	  achieved.	  	  Do	  not	  place	  undue	  reliance	  on	  these	  projec/ons.	  	  	  
First Decade 
of Commercialization
Second Decade 
of Commercialization
Our	  interdisciplinary	  team	  has	  the	  ability	  	  
to	  idenCfy	  and	  diligence	  cross-­‐discipline	  deals.	  	  
OUR EXPERTISE IS INTERDISCIPLINARY
Physics	  
Biology	  
Materials	  
Science	  
Engineering	  
Medicine	  
Nanotechnology	  
Chemistry	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Biofuels	  
LighCng	  
Energy	  HarvesCng	  
Ba`eries	  
Renewable	  Chemicals	  
Water	  
Molecular	  DiagnosCcs	  
Touch	  Screens	  
Drug	  Discovery	  
3D	  Biology	  
Cancer	  TherapeuCcs	  
???	  
Disposable	  Electronics	  
Image	  Sensors	  
Quantum	  CompuCng	  
Solid	  State	  Memory	  
Vaccines	  
These	  discoveries	  cross-­‐ferClize	  mulCple	  billion-­‐dollar	  end	  markets	  
resulCng	  in	  a	  diverse	  porLolio.	  
OUR APPROACH YIELDS A DIVERSE PORTFOLIO 
8	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OUR PORTFOLIO COMPANIES 
ADDRESS NEEDS IN MANY INDUSTRIES
Note: The portfolio companies listed are ones in which 
Harris & Harris Group made its initial investment since 
2002.  This time period was chosen based on the year 
that the first of the current managing directors joined 
the firm. 
CORPORATE INVOLVEMENT IS CRITICAL
	  	  
Corporate	  involvement	  is	  criCcal	  to	  providing	  scale	  and	  distribuCon.	  	  Understanding	  the	  
opCmal	  transiCon	  point	  is	  quintessenCal	  to	  build	  capital	  eﬃcient	  businesses.	  	  	  
EARLY-­‐STAGE	  
DEVELOPMENT	  
Characteriza/on,	  reproducibility,	  
Base	  line	  processes,	  
Integra/on	  challenges,	  
Speciﬁca/on	  challenge	  
Correct	  cost	  model	  
	  
SCALE	  AND	  
MANUFACTURING	  
Manufacturing	  scale,	  
Factory	  integra/on,	  pilot	  
facili/es,	  	  
Clinical	  Trials	  
$$
	  
TIME	  
REVENUE	  GROWTH	  
Introduc/on	  and	  access	  to	  
the	  market	  &	  customers	  
Value	  CreaCon	  
CumulaCve	  Cost	  
Deal	  team	  
Strengths	  
AcCve	  Corporate	  
	  	  	  	  Involvement	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OUR PARTNERS - PRESENT
Note: All numbers are as of June 30, 2012.  The amounts listed are from portfolio companies in which 
Harris & Harris Group made its initial investment since 2002.  This time period was chosen based on 
the year that the first of the current managing directors joined the firm.
Over $80 million 
in federal funding
Over two thirds have 
significant corporate 
partnerships or investors
> $1 billion in capital from 
other venture capital firms
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$149 million 
Invested by 
H&H
Alloy Ventures
ARCH Venture Partners
ATA Ventures
Battery Ventures
Braemar Energy Ventures
CMEA Capital
Crosslink Ventures
DCM – Doll Capital 
Management 
Draper Fisher Jurvetson
Energy Ventures
Fidelity Biosciences
Globespan Capital Partners
Khosla Ventures
KPCB
Proquest
Polaris Venture Partners
Venrock
Bosch
Bristol Myers Squibb
Bunge
Coherent
Chevron
Dow
Hitachi Chemical
IMAX
Intel
LG Innotek 
Lockheed Martin
Mitsui
Panasonic
Pfizer
Samsung 
Sephora
Schlumberger
Synaptics
Syngenta
Tyco 
Unilever
Columbia University
California Institute of Technology
Harvard University 
Lawrence Berkeley Laboratory
Massachusetts General Hospital
Massachusetts Institute of Technology
Research Triangle Institute 
University of California
University College London
University of Illinois Urbana Champaign 
University of Texas
Whitehead Institute
Advanced Defense Research Projects Agency
National Science Foundation
National Institute for Standards and Technology
Night Vision and Electronic Sensors Directorate
Office of Naval Research
National Institutes of Health 
Department of Energy
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OUR PARTNERS - FUTURE
Government 
Agencies 
Corporate 
Partners
Venture Capital Firms
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Capital 
from H&H
Permanent capital of Harris & Harris Group 
invested alongside outside capital managed by 
Harris & Harris Group.
Uncertain future for availability of government grants, 
contracts, loan guarantees.
Corporations have capital and need 
visibility and access to disruptive 
technologies in core and adjacent 
markets.
Number and size of venture capital firms 
investing in energy, healthcare and 
electronics are decreasing, which reduces 
capital availability from these sources.
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PRIORITIES FOR 2012 AND BEYOND
We currently believe Harris & Harris Group is well positioned to 
grow its NAV and generate returns for shareholders through:
 •  Liquidity Events:
•  Between 2012 and 2014, we believe our late-stage companies could 
reach liquidity through IPOs or sales. 
•  We believe more than 75 percent of our mid-stage companies could be 
in a position to complete transactions that create liquidity for our 
investments in those companies.
•  Generating Predictable and Near-Term Income:
•  We are investigating opportunities to increase our venture debt 
investment opportunities.
•  We are selling call options covered by our positions in publicly traded 
portfolio companies.
•  Increasing Investable Assets Without Issuing Common Stock
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Note:  These projections are based on currently available information and the timelines for reaching and the percentages 
of our current portfolio companies that may reach liquidity events may differ materially in the future from these 
projections. There can be no assurance that any of these companies will be able to consummate either type of transaction, 
or that a successful liquidity event by any of these companies will generate a positive return on invested capital. 
THE CHANGING DIALOGUE
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•  Diminishing	  	  early-­‐stage	  ﬁnancings	  
creates	  opportuniCes:	  
o  Outstanding	  pipeline	  of	  deals.	  
o  Ability	  to	  nego/ate	  favorable	  
deal	  terms.	  
	  
•  Early	  stage	  nanotech	  deals	  require	  
our	  speciﬁc	  skills	  and	  involvement:	  
o  Technology	  development.	  
o  IP	  landscape	  development.	  
o  Management	  team	  
development.	  
o  Venture	  syndica/on.	  
o  Product	  and	  market	  
deﬁni/on.	  
o  Need	  for	  corporate	  partners.	  
FOCUS ON EARLY STAGE
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First	  InsCtuConal	  Investor	  or	  Part	  of	  First	  InsCtuConal	  Syndicate 
•  ABSMaterials	  
•  Adesto	  
•  Ancora	  
•  Bridgelux	  
•  Contour	  Energy	  
•  Enumeral	  
•  HzO	  
•  Laser	  Light	  Eng.	  
•  Mersana	  
•  Nantero(1)	  
•  Nextreme	  
•  Senova	  
•  SiOnyx	  
•  Ultora	  
•  Xradia	  
•  Adap/ve	  Web	  (Exited	  in	  2001)(1)	  
•  Ag	  Services	  of	  America	  (Exited	  in	  1993)(1)	  
•  Agile	  (Exited	  in	  2005)	  
•  Alliance	  Pharma.	  (Exited	  in	  1990,	  1997	  and	  2000)(1)	  
•  American	  Equine	  Products	  (Exited	  in	  1990)(1)	  
•  Chlorogen	  (Exited	  in	  2008)	  
•  CORDEX	  Petroleums	  (Exited	  in	  1998)(1)	  
•  Crystal	  IS	  (Exited	  in	  2011)	  
•  Cswitch	  (Exited	  in	  2009)	  
•  Evolved	  Nanomaterial	  Sciences	  (Exited	  in	  2008)(1)	  
•  Experion	  Systems	  (Exited	  in	  2005)(1)	  
•  Genomica	  (Exited	  in	  2001)(1)	  
•  Molten	  Metal	  Technology	  (Exited	  in	  1993)(1)	  
•  NanoGram	  (Exited	  in	  2010)	  
•  NanoGram	  Devices	  (Exited	  in	  2005)	  
•  NBX	  (Exited	  in	  1999)(1)	  
•  NeoPhotonics	  (IPO	  in	  2011)(2)	  
•  NeuroMetrix	  (Exited	  in	  2005)(1)	  
•  Phoenix	  Molecular	  (Exited	  in	  2008)	  
•  Questech	  (Exited	  in	  2011)(1)	  
•  Re	  Capital	  (Exited	  in	  1989)(1)	  
•  SciQuest	  (Exited	  in	  2000)(1)	  
•  Silknet	  Sofware	  (Exited	  in	  2001)(1)	  
•  Siluria	  (Exited	  in	  2011)	  
•  Solazyme	  (IPO	  in	  2011)(2)	  
•  Starﬁre	  (Exited	  in	  2009)	  
•  Sundial	  (Exited	  in	  2001)(1)	  
•  Voice	  Control	  Sys.	  (Exited	  in	  1999)(1)	  
•  Zia	  Laser	  (Exited	  in	  2008)	  
(1)  IniCal	  investment	  made	  prior	  to	  2002.	  	  The	  ﬁrst	  member	  of	  the	  current	  investment	  team	  joined	  Harris	  &	  Harris	  Group	  in	  2002.	  
(2)  	  NeoPhotonics	  and	  Solazyme	  remain	  as	  unrealized	  porLolio	  holdings	  as	  of	  June	  30,	  2012.	  
WE ARE EARLY-STAGE 
ACTIVE INVESTORS
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H&H TECHNOLOGY 
DOMAINS
BIOTECHNOLOGY CHEMICAL ELECTRONICS
Precision Chemistry Novel Medicines Novel Chemical Synthesis
Nanoscale, molecular, 
macromolecular modeling.
Nano-Fluidics  & 
Fabrication 
Novel, multiplexed, small-volume 
sample handling.
Novel materials for low cost 
analysis. 
Nanofluidic control systems and 
macroscale integration.
Separations 
Efficiently purify water and 
proteins.
Novel resins and 
membranes.
Modeling and optimization of 
separation systems.
Sensing 
Nano-scale sensors for molecular 
analysis and bioprocess 
monitoring.
Novel materials and 
chemistry for low cost 
remote sensing. 
Dispersed sensor systems, 
mesh/adaptive networks, multi and 
hyper-spectral imaging.
Semiconductors & 
Molecular Analysis 
Semiconductor based technology 
for genetic and biochemical 
analysis.
Novel circuit board 
substrate materials & 
chemistry. 
High-density, high-speed memory 
and data storage.
Big Data 
Biomarker discovery and better 
decision making for patient care. 
Algorithms for novel 
chemical and materials 
design. 
High-speed memory and 
interconnects, multi-variable 
processing, unstructured to 
structured data sets.
3D Biology 
3D cell printing and propagation 
for diagnostics and discovery.
Advanced materials for 3D 
tissue regeneration and 
growth. 
Protein and tissue modeling.
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HARRIS & HARRIS GROUP TECHNOLOGY DOMAINS 
ARE RELEVANT TO SEVERAL INDUSTRIES
  
FROM	  DIGITAL	  TO	  QUANTUM	  COMPUTING	  
Harness	  the	  ability	  of	  quantum	  mechanics	  to	  solve	  some	  of	  the	  
most	  computaConally	  intensive	  problems	  in	  seconds	  or	  
minutes	  rather	  than	  years.	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D-WAVE SYSTEMS
SuperconducCng	  	  
Josephson	  JuncCons	  
Integrated	  SuperconducCng	  	  
Circuits	  
AdiabaCc	  quantum	  
computer	  
with	  partners	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